SPLASH Trial Highlights Radiopharmaceutical Lutetium-177's Role in Advanced Prostate ...
The SPLASH trial evaluates Lutetium-177-PNT2002 in metastatic castration-resistant prostate cancer patients progressing on ARPI therapy, showing significant improvement in radiographic progression-free survival with a hazard ratio of 0.71. Dr. Sartor highlights the favorable safety profile and efficacy, including higher objective response rates and PSA responses, but notes the high crossover rate (84.6%) from the control arm to Lutetium therapy, potentially affecting overall survival results. The unique dosing schedule of this agent, compared to other Lutetium-177 therapies, is discussed for its potential advantages in reduced toxicity. The evolving landscape of radiopharmaceuticals, including dose optimization, new isotopes, and combination therapies, is emphasized for increased treatment options.
Reference News
The SPLASH trial evaluates Lutetium-177-PNT2002 in metastatic castration-resistant prostate cancer patients progressing on ARPI therapy, showing significant improvement in radiographic progression-free survival with a hazard ratio of 0.71. Dr. Sartor highlights the favorable safety profile and efficacy, including higher objective response rates and PSA responses, but notes the high crossover rate (84.6%) from the control arm to Lutetium therapy, potentially affecting overall survival results. The unique dosing schedule of this agent, compared to other Lutetium-177 therapies, is discussed for its potential advantages in reduced toxicity. The evolving landscape of radiopharmaceuticals, including dose optimization, new isotopes, and combination therapies, is emphasized for increased treatment options.